Clinical study of APN01 for COVID-2019-infections
Latest Information Update: 02 Jun 2021
At a glance
- Drugs APN 401 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 02 Jun 2021 New trial record
- 01 Jun 2021 According to an Apeiron Biologics media release, this large-scale study will be funded by the U.S. government which is scheduled to start in Q2 2021.